Viridian Therapeutics (NASDAQ:VRDN) Given New $34.00 Price Target at Wells Fargo & Company

Viridian Therapeutics (NASDAQ:VRDN) had its price target hoisted by Wells Fargo & Company from $31.00 to $34.00 in a research report report published on Thursday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other research analysts also recently weighed in on VRDN. Needham & Company LLC boosted their target price on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings raised shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 14th. HC Wainwright lifted their price target on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen lowered shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Finally, Royal Bank Of Canada boosted their price objective on shares of Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Tuesday, September 22nd. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Viridian Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.00.

Viridian Therapeutics Trading Down 1.8%

Shares of Viridian Therapeutics stock opened at $28.55 on Thursday. The company has a 50-day moving average of $21.88 and a two-hundred day moving average of $21.83. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The stock has a market cap of $3.23 billion, a PE ratio of -7.43 and a beta of 1.07.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.21. The business had revenue of $25.75 million for the quarter, compared to analyst estimates of $4.72 million. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 77.15%. On average, research analysts anticipate that Viridian Therapeutics will post -4.07 EPS for the current fiscal year.

Insider Activity at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VRDN. Knights of Columbus Asset Advisors LLC raised its stake in Viridian Therapeutics by 27.6% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 90,019 shares of the company’s stock worth $1,853,000 after purchasing an additional 19,466 shares during the period. 71 West Capital Partners grew its stake in shares of Viridian Therapeutics by 4.1% during the 3rd quarter. 71 West Capital Partners now owns 22,282 shares of the company’s stock valued at $459,000 after buying an additional 882 shares during the period. Fulcrum Asset Management LLP purchased a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at $97,000. Pictet Asset Management Holding SA increased its holdings in shares of Viridian Therapeutics by 13.5% during the 3rd quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company’s stock worth $262,000 after buying an additional 1,516 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Viridian Therapeutics during the 3rd quarter worth $216,000.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Multiple firms raised their price targets and maintained or initiated positive ratings. On Nov. 5, Leerink Partners lifted its target to $54 and RBC to $41, both with “outperform” ratings; Truist raised its target to $42 (“buy”), while Wells Fargo, Wedbush and HC Wainwright also increased targets. Leerink Partners rating
• Positive Sentiment: Viridian’s Q3 loss of $0.81 per share was narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million topped the $4.72 million consensus. The earnings beat may have helped support investor sentiment, although the per-share loss widened from $0.34 a year earlier. Q3 results
• Positive Sentiment: Viridian outlined commercial and pipeline milestones: Lumvoa’s launch is targeting broad coverage within six to nine months, and the company signaled a biologics license application for elegrobart in Q1 2027. Progress toward broader access and the regulatory filing could strengthen the growth outlook, though execution remains important. Lumvoa and elegrobart milestones
• Negative Sentiment: A separate valuation analysis argued VRDN could be overvalued even with its new product launch, which may temper enthusiasm following the rally and analyst target increases. Valuation analysis

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.